Aerie Pharmaceuticals
Alcon successfully completes its acquisition of Aerie Pharmaceuticals, expanding its ophthalmic pharmaceutical portfolio with Rocklatan and Rhopressa and adding significant R&D expertise in eye care.
Basic Information
- Category: pharmaceutical industry
- Website: http://www.aeriepharma.com/
Documented Facts
- Inception (Wikidata): 2005-01-01 (Source 6: Wikidata Q25245434, revision 2534624193)
- Industry (Wikidata; date unspecified): pharmaceutical industry (Source 6: Wikidata Q25245434, revision 2534624193; Source 7: Wikidata label: Q507443, revision 2542338100)
- Country (Wikidata; date unspecified): United States (Source 6: Wikidata Q25245434, revision 2534624193; Source 8: Wikidata label: Q30, revision 2556188301)
- Official website (Wikidata; date unspecified): http://www.aeriepharma.com/ (Source 6: Wikidata Q25245434, revision 2534624193)
Evidence and Sources
- Aerie Pharmaceuticals — Official Site (official)
- Aerie Pharmaceuticals on instagram (social)
- Aerie Pharmaceuticals on facebook (social)
- Aerie Pharmaceuticals on linkedin (social)
- Aerie Pharmaceuticals — Wikipedia (reference)
- Wikidata Q25245434, revision 2534624193 (knowledge-base)
- Wikidata label: Q507443, revision 2542338100 (knowledge-base)
- Wikidata label: Q30, revision 2556188301 (knowledge-base)
Citation Guidance
Explore pharmaceutical industry profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Aerie Pharmaceuticals.
- Canonical profile: https://brandsource.ai/brands/aerie-pharmaceuticals
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/aerie-pharmaceuticals/json-ld
- Citation profile API: https://brandsource.ai/api/brands/aerie-pharmaceuticals/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Alcon successfully completes its acquisition of Aerie Pharmaceuticals, expanding its ophthalmic pharmaceutical portfolio with Rocklatan and Rhopressa and adding significant R&D expertise in eye care.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 7 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.